NeoGenomics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di NeoGenomics sono diminuiti a un tasso medio annuo di -46.7%, mentre il settore Healthcare ha visto gli utili crescere a un tasso medio annuo di 5.3%. I ricavi sono cresciuti crescere a un tasso medio annuo di 9.7%.

Informazioni chiave

-46.7%

Tasso di crescita degli utili

-46.2%

Tasso di crescita dell'EPS

Healthcare Crescita del settore	8.5%
Tasso di crescita dei ricavi	9.7%
Rendimento del capitale proprio	-8.6%
Margine netto	-12.1%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

Ripartizione dei ricavi e delle spese

Come NeoGenomics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqCM:NEO Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	644	-78	323	30
30 Jun 24	628	-79	327	28
31 Mar 24	611	-84	321	28
31 Dec 23	592	-88	313	27
30 Sep 23	575	-96	315	27
30 Jun 23	552	-115	318	29
31 Mar 23	530	-126	312	30
31 Dec 22	510	-144	311	30
30 Sep 22	497	-163	293	32
30 Jun 22	489	-147	303	32
31 Mar 22	486	-36	291	27
31 Dec 21	484	-8	284	22
30 Sep 21	485	49	255	15
30 Jun 21	489	72	211	10
31 Mar 21	454	-11	196	9
31 Dec 20	444	4	192	8
30 Sep 20	425	-5	187	8
30 Jun 20	405	-5	184	9
31 Mar 20	419	3	182	9
31 Dec 19	409	8	175	8
30 Sep 19	378	2	164	7
30 Jun 19	343	2	147	5
31 Mar 19	309	6	134	3
31 Dec 18	277	6	114	3
30 Sep 18	262	8	103	3
30 Jun 18	252	-1	100	4
31 Mar 18	246	-9	96	4
31 Dec 17	240	-11	94	4
30 Sep 17	239	-27	98	4
30 Jun 17	241	-26	98	4
31 Mar 17	242	-29	99	4
31 Dec 16	232	-31	88	5
30 Sep 16	211	-18	85	6
30 Jun 16	175	-12	70	5
31 Mar 16	136	-7	55	5
31 Dec 15	100	-3	41	4
30 Sep 15	98	0	39	3
30 Jun 15	96	0	39	3
31 Mar 15	92	0	38	3
31 Dec 14	87	1	36	3
30 Sep 14	80	1	33	3
30 Jun 14	74	2	31	2
31 Mar 14	69	2	28	2
31 Dec 13	66	2	26	2

Guadagni di qualità: NEO al momento non è redditizia.

Margine di profitto in crescita: NEO al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: NEO non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 46.7% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di NEO nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: NEO non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Healthcare ( 10.3% ).

Rendimento del capitale proprio

ROE elevato: NEO ha un Return on Equity negativo ( -8.56% ), in quanto al momento non è redditizio.

NeoGenomics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2024 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Consensus EPS estimates fall by 15%

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics gets new CEO

Price target decreased to US$17.75

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

Consensus EPS estimates fall by 21%

President & COO of Lab Operations notifies of intention to sell stock